Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761810 · ClinicalTrials.gov registry record · Phase 3
A Study of S6G5T3 in the Treatment of Acne Vulgaris
A Phase 3 study of Acne Vulgaris, sponsored by Sol-Gel Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 434
- Enrollment target
- 1
- Study location
NCT03761810 is a Phase 3 study of Acne Vulgaris that has completed, run by Sol-Gel Technologies. The registered enrollment target is 434 participants, above the 269-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (61% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03761810, a Phase 3 study of Acne Vulgaris, has completed, sponsored by Sol-Gel Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 434 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the efficacy of S6G5T-3 compared to its vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
Conditions Studied
Interventions
- DRUG S6G5T-3
- DRUG S6G5T-8
Study Locations (1)
Florida
- Sol-Gel site 501 - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 434 participants |
| Start Date | 2018-12-14 |
| Est. Completion | 2019-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03761810
The ClinicalTrials.gov registry entry for NCT03761810 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 434 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 269-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (61% higher). The listed sponsor is Sol-Gel Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which S6G5T-3 is the first listed.
NCT03761810 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03761810 about?
NCT03761810 is a clinical study titled "A Study of S6G5T3 in the Treatment of Acne Vulgaris". To assess the efficacy of S6G5T-3 compared to its vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
What is the current status of trial NCT03761810?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 434 participants. The study started on 2018-12-14. Estimated completion is 2019-10-23.
What conditions does trial NCT03761810 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT03761810?
The interventions under investigation include: S6G5T-3 (DRUG), S6G5T-8 (DRUG).
Who is sponsoring clinical trial NCT03761810?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03761810 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
COMPLETED · Phase 3
-
P3 Long Term Safety Study of Once Daily SB204 in Acne
COMPLETED · Phase 3
-
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
COMPLETED · Phase 3
-
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
-
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.